FDA Approves New Combination Treatment for Renal Cell Carcinoma
Merck’s KEYTRUDA Combination Receives FDA Approval for Kidney Cancer Adjuvant Treatment Merck & Co. (NYSE: MRK) secured FDA approval for its KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) ... Read More